Effect of Cilostazol on platelet activation in pateints with type 2 diabetes mellitus

Effect of Cilostazol on platelet activation in pateints with type 2 diabetes mellitus - Effect of Cilostazol on platelet activation in pateints with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004373

Enrollment

Registered

2010-10-13

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

The medication for the anti-platelet therapy in participants is changed from aspirin to cilostazol (200mg per day) and they continue this medication for 2 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetic patients who took aspirin and showed the formation of spontaneous micro-aggregation of platelets (SMAP)

Exclusion criteria

Exclusion criteria: 1) diabetic patients except type 2 diabetes 2) patients below 20 years of age 3) pregnant pateints or the lactation period 4) complicated with malignacy, liver disease and collagen disease 5) taking any NSAIDs within 2 weeks 6) past history of bleeding within 6 weeks or bleeding tendency 7) complicated with sever coronary stenosis

Design outcomes

Primary

Measure	Time frame
1) the formation of spontaneous maicro-aggregation of platelet (SMAP) 2) the expression levels of active GPIIb/IIIa and P-selectin on the platelet	—

Countries

Japan

Contacts

Public ContactShin-ichi Araki

Shiga University of Medical Science Internal medicine

araki@belle.shiga-med.ac.jp077-548-2222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026